Contrary to the traditional view of the health care consumer as an economic agent whose sove-reignty is attenuated, we argue that he is far less ignorant and far less deprived of reason than it is supposed by the tutelary model of health economics. The reason lies in his enhanced level of...

L'évaluation économique est pertinente pour appréhender les stratégies thérapeutiques des maladies chroniques. Celles-ci posent néanmoins des difficultés d'application qui peuvent exister dans les maladies aiguës mais sont cumulées dans les maladies chroniques (horizon de long terme,...

Introduction : Benefit-risk of different anti-rabies post-exposure prophylaxis (PEP) strategies after scratches or bites from dogs with unknown rabies status is unknown in very low rabies risk settings. Design and setting : A cost-effectiveness analysis in metropolitan France using a...

Objectives To assess the efficacy and the cost of a French team work experiment between nurses and GPs for managing type 2 diabetes patients. Methods Based on a case control study design we compare the evolution of process (standard follow-up procedures) and final (glycemic control) outcomes,...

Background Patent expiries on leading biologics are creating new momentum in the market for biosimilars (copies of off-patent biologics), paving the way for their development. However, little is known about the factors influencing the competition between biosimilars and their reference products...

Background In 2009, a voluntary-based pay for performance scheme targeting general practitioners (GPs) was introduced in France through the ‘Contract for Improving Individual Practices’ (CAPI). Objective To study the impact of the CAPI on French GPs’ consultation length. Methods Univariate...

Objective: The objective of the study was to compute a cost-effectiveness ratio relating the economic cost of trandolapril to the number of effectiveness units (i.e. life-years) gained. Design and Setting: The trandolapril cardiac evaluation (TRACE) study was a prospective placebo-controlled...

The availability of the Diagnosis Related Group (DRG) system for determining hospital costs in some European countries has encouraged its use in pharmacoeconomic evaluations. The DRG system was developed in the US to provide data for prospective payments for hospitals. However, the financing of...